Antidepressants: Controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach

World Journal of Biological Psychiatry

Volumn 10, Issue 3, 2009, Pages 180-195

  Möller, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antidepressants; Complex psychiatric treatment; Depression; Efficacy; Suicidality

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; ESCITALOPRAM; LITHIUM; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGE; AGITATION; ANOREXIA; ANXIETY DISORDER; ATTRIBUTABLE RISK; CLINICAL DECISION MAKING; COGNITIVE THERAPY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GLAUCOMA; GOOD CLINICAL PRACTICE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPNOSIS; INDIVIDUALIZATION; INSOMNIA; MELANCHOLIA; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PHARMACOGENETICS; PSYCHIATRIC TREATMENT; PSYCHOEDUCATION; PSYCHOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUICIDAL BEHAVIOR; URINE RETENTION;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DECISION MAKING; DEPRESSIVE DISORDER; HUMANS; PSYCHOTHERAPY; SUICIDE; TREATMENT OUTCOME;

EID: 68549090869     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970903101665     Document Type: Review

References (103)

1. Anderson IM 2000. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. J Affect Disord 58:19-36.
2. Angst J, Angst F, Gerber-Werder R, Gamma A 2005. Suicide in 406 mood-disorder patients with and without long-term medication: A 40 to 44 years' follow-up. Arch Suicide Res 9:279-300.
3. Baghai TC, Volz HP, Möller HJ 2006. Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 7:198-222.
4. Balazs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS 2006. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 91:133-138.
5. Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ 2003. Placebo-controlled studies in depression: Necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 253:22-28.
6. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, Task Force on Treatment Guidelines for Unipolar Depressive Disorders. WFSBP 2002. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5-43.
7. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al 2007. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 8:67-104.
8. Bauer M, Tharmanathan P, Volz HP, Möller HJ, Freemantle N 2009. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis. Eur Arch Psychiatry Clin Neurosci 259: 172-185.
9. Beck AT, Rush AJ, Shaw BF 1979. Cognitive therapy of depression. New York: Guilford.
10. Belmaker RH, Agam G 2008. Major depressive disorder. New Engl J Med 358:55-68.
11. Caspi A, Moffitt TE 2006. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 7:583-590.
12. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al 2003. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 301:386-389.
13. Cuijpers P, van Straten A, Warmerdam L 2007a. Behavioral activation treatments of depression: A meta-analysis. Clin Psychol Rev 27:318-326.
14. Cuijpers P, van Straten A, Warmerdam L 2007b. Problem solving therapies for depression: A meta-analysis. Eur Psychiatry 22: 9-15.
15. de Maat S, Dekker J, Schoevers R, van Aalst G, Gijsbers-van Wijk C, Hendriksen M, et al 2008. Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: A mega-analysis based on three randomized clinical trials. Depress Anxiety 25(7):565-574.
16. Eser D, Baghai TC, Möller HJ 2007. Evidence of agomelatine's antidepressant efficacy: The key points. Int Clin Psychopharmacol 22(Suppl 2):S15-19.
17. Eser D, Baghai T, Möller HJ. 2008. Agomelatine: The evidence for its place in the treatment of depression. Core Evidence 3(2):109-116.
18. FDA Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications. (2004) .
19. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al 2005. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. Br Med J 330:396.
20. Friedman MA, Detweiler-Bedell JB, Leventhal HW, Horne R, Keitner GI, Miller IW 2004. Combined psychotherapy and pharmacotherapy for the treatment of depression disorder. Clin Psychol Sci Pract 11:47-68.
21. Fritze J, Möller HJ 2001. Design of clinical trials of antidepressants. Should a placebo control arm be included? CNS Drugs 15(10):755-764.
22. Frodl T, Meisenzahl EM, Zill P, Baghai T, Rujescu D, Leinsinger G, et al 2004. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry 61:177-183.
23. Frodl T, Moller HJ, Meisenzahl E 2008. Neuroimaging genetics: New perspectives in research on major depression? Acta Psychiatr Scand 118:363-372.
24. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al 2003. Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. Lancet 361:653-661.
25. Geddes JR, Cipriani A 2004. Selective serotonin reuptake inhibitors. Br Med J 329:809-810.
26. Hammad T. 2004. Review and evaluation of clinical data: Relationship between psychotropic drugs and pediatric suicidality. .
27. Hammad TA, Laughren T, Racoosin J 2006. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339.
28. Hegerl U, Gallinat J, Juckel G 2001. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 62:93-100.
29. Hegerl U, Plattner A, Moller HJ 2004. Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s. Eur Arch Psychiatry Clin Neurosci 254:99-107.
30. Hegerl U, Hautzinger M, Mergl R, Kohnen R, Schütze M, Scheunemann W, et al. 2008. Effects of pharmaco-and psychotherapy in depressed primary care patients: A randomised, controlled trial including a patient choice arm. J Clin Psychiatry.
31. Henkel V, Seemuller F, Obermeier M, Adli M, Bauer M, Mundt C, et al 2009. Does early improvement triggered by antidepressants predict response/remission? -Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 115:439-449.
32. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, et al 2002. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63:826-837.
33. Kato T 2007. Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 61:3-19.
34. Keller MB 2002. Rationale and options for the long-term treatment of depression. Hum Psychopharmacol 17(Suppl 1):S43-46.
35. Keller MB, Gelenberg AJ, Hirschfeld RM, Rush AJ, Thase ME, Kocsis JH, et al 1998. The treatment of chronic depression, part 2: A double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 59:598-607.
36. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, et al 2000. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New Engl J Med 342:1462-1470.
37. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, et al 2007. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 68:1246-1256.
38. Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, et al. 2009. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: The THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 13: iii-xi, 1.
39. Kirsch I, Moore TJ, Scoboria A, Nicholls S. 2002. The emperor's new drugs: An analyses of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment 5(article 23).
40. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT 2008. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45.
41. Klein DF. 1998. Listening to meta-analysis but hearing bias. Prevention & Treatment 1.
42. Klerman GL, Weissmann MM. 1987. Interpersonal psychotherapy (IPT) and drugs in the treatment of depression. Pharmacopsychiatry 20(1):3-7.
43. Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, et al 2001. Sertraline versus imipra mine to prevent relapse in chronic depression. J Affect Disord 65:27-36.
44. Lepine JP, Caillard V, Bisserbe JC, Troy S, Hotton JM, Boyer P 2004. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 161:836-842.
45. Lepola U, Wade A, Andersen HF 2004. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 19:149-155.
46. Lerer B, Macciardi F 2002. Pharmacogenetics of antidepressant and mood-stabilizing drugs: A review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 5:255-275.
47. Llorca PM, Azorin JM, Despiegel N, Verpillat P 2005. Efficacy of escitalopram in patients with severe depression: A pooled analysis. Int J Clin Pract 59:268-275.
48. Mallinckrodt CH, Prakash A, Houston JP, Swindle R, Detke MJ, Fava M 2007. Differential antidepressant symptom efficacy: Placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology 56:73-85.
49. Melander H, Salmonson T, Abadie E, Zwieten-Boot B. 2008. A regulatory apologia - A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18(9):623-627.
50. Möller HJ 1992a. Antidepressants - do they decrease or increase suicidality? Pharmacopsychiatry 25:249-253.
51. Möller HJ 1992b. Attempted suicide: Efficacy of different aftercare strategies. Int Clin Psychopharmacol 6(Suppl 6):58-69.
52. Möller HJ 2000. Rating depressed patients: Observer- vs selfassessment. Eur Psychiatry 15:160-172.
53. Möller HJ. 2003. Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand Suppl. 418:73-80.
54. Möller HJ 2005. Therapieresistenz unipolarer depressiver Erkrankungen: Häufigkeit, Prädiktoren, Risikofaktoren. In: Bauer M, Berghöfer A, Adli M, editors. Akute und therapieresistente Depression. 2. Aufl. ed. Heidelberg: Springer. p 21-38.
55. Möller HJ 2006a. Evidence for beneficial effects of antidepressants on suicidality in depressive patients: A systematic review. Eur Arch Psychiatry Clin Neurosc 256:329-343.
56. Möller HJ. 2006b. Pharmacological/clinical mechanisms by which antidepressants could theoretically induce suicidal ideations or behaviour. In preparation.
57. Möller HJ 2008a. Is the identification of the core symptoms of depression clinically relevant? Medicographia 30:3-8.
58. Möller HJ 2008b. Is there a need for a new psychiatric classification at the current state of knowledge? World J Biol Psychiatry 9:82-85.
59. Möller HJ. 2008c. Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the meta-analysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci. 258(8):451-5.
60. Möller HJ 2008d. Methodik empirischer Forschung. In: Möller HJ, Laux G, Kapfhammer H-P, editors. Psychiatrie und Psychotherapie. 3. Aufl. Band 1 ed. Heidelberg: Springer. p 346-367.
61. Möller HJ 2008e. Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment. World J Biol Psychiatry 9:102-114.
62. Möller HJ 2009. Standardised rating scales in Psychiatry: Methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry 10:6-26.
63. Möller HJ, Maier W 2007. Probleme der "evidence-based medicine" in der Psychopharmakotherapie. Problematik der Evidenzgraduierung und der Evidenzbasierung komplexer klinischer Entscheidungsprozesse. Nervenarzt 78:1014-1027.
64. Möller HJ, Maier W. 2009. Evidence-based Medicine in Psychiatry. Eur Arch Psychiatry Clin Neurosci in press.
65. Möller HJ, von Zerssen D 1995. Self-rating procedures in the evaluation of antidepressants. Psychopathology 28:291-306.
66. Möller HJ, Fischer G, von Zerssen D 1987. Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients. Eur Arch Psychiatry Neurol Sci 236: 349-357.
67. Möller HJ, Langer S, Schmauss M 2007. Escitalopram in clinical practice: Results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry 40:53-57.
68. Möller HJ, Baldwin DS, Goodwin G, Kasper S, Okasha A, Stein DJ, et al 2008. Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: Consensus statement. Eur Arch Psychiatry Clin Neurosci 258(Suppl 3): 3-23.
69. Moncrieff J, Kirsch I 2005. Efficacy of antidepressants in adults. Br Med J 331:155-157.
70. Montgomery SA, Kasper S 2007. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 22:283-291.
71. Montgomery SA, Möller HJ 2009. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 24:111-118.
72. Montgomery SA, Bech P, Blier P, Möller HJ, Nierenberg AA, Pinder RM, et al 2002. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 63:694-699.
73. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al 2007. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323-329.
74. National Institute for Clinical Excellence. 2004. Depression: Management of depression in primary and secondary care. Clinical practice guideline No 23. London: National Institute for Clinical Excellence.
75. Papakostas GI, Thase ME, FavaM, Nelson JC, Shelton RC 2007. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62:1217-1227.
76. Parker G 2000. Classifying depression: Should paradigms lost be regained? Am J Psychiatry 157:1195-1203.
77. Parker G 2002. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 106:168-170.
78. Paykel ES 2007. Cognitive therapy in relapse prevention in depression. Int J Neuropsychopharmacol 10:131-136.
79. Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R, et al 1999. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 56:829-835.
80. Reynolds CF III, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, et al 2006. Maintenance treatment of major depression in old age. New Engl J Med 354:1130-1138.
81. Rush AJ 2007. STAR·D: What have we learned? Am J Psychiatry 164:201-204.
82. Rush AJ, Koran LM, Keller MB, Markowitz JC, Harrison WM, Miceli RJ, et al 1998. The treatment of chronic depression, part 1: Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry 59:589-597.
83. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C 2004. Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology (Berlin) 174:163-176.
84. Schaub A, Roth E, Goldmann U 2006. Kognitiv-Psychoedukative Therapie zur Bewältigung von Depressionen: Ein Therapiemanual. Göttingen: Hogrefe.
85. Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, et al 2005. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2:590-611.
86. Seemüller F, Riedel M, Obermeier M, Bauer M, Adli M, Mundt C, et al 2009. The controversial link between antidepressants and suicidality risks in adults: Data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int J Neuropsychopharmacol 12:181-189.
87. Sharan P, Saxena S 1998. Treatment-resistant depression: Clinical significance, concept and management. Natl Med J India 11:69-79.
88. Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A 2007. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 68:1195-1205.
89. Stone MB, Jones ML. 2006. Clinical review: Relationship between antidepressant drugs and suicidality in adults. .
90. Storosum JG, Elferink AJ, van Zwieten BJ, van den BW, Gersons BP, van Strik R, et al 2001. Short-term efficacy of tricyclic antidepressants revisited: A meta-analytic study. Eur Neuropsychopharmacol 11:173-180.
91. Sullivan PF, Neale MC, Kendler KS 2000. Genetic epidemiology of major depression: Review and meta-analysis. Am J Psychiatry 157:1552-1562.
92. Tadic A, Muller MJ, Rujescu D, Kohnen R, Stassen HH, Dahmen N, et al 2007. The MAOA T941G polymorphism and shortterm treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet 144B:325-331.
93. Teicher MH, Glod CA, Cole JO 1993. Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 8:186-212. Thase ME, Entsuah AR, Rudolph RL 2001. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241.
94. Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, et al 2002. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 59:233-239.
95. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ 2007. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 27:672-676.
96. Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH, et al 2006. Implementation of the Texas Medication Algorithm Project patient and family education program. J Clin Psychiatry 67:1362-1372.
97. Trindade E, Menon D, Topfer LA, Coloma C 1998. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis. CMAJ 159:1245-1252.
98. Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, et al 2004. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 61:669-680.
99. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR·D: Implications for clinical practice. Am J Psychiatry 163:28-40.
100. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R 2008. Selective publication of antidepressant trials and its influence on apparent efficacy. New Engl J Med 358:252-260.
101. Vaiva G, Vaiva G, Ducrocq F, Meyer P, Mathieu D, Philippe A, et al 2006. Effect of telephone contact on further suicide attempts in patients discharged from an emergency department: Randomised controlled study. Br Med J 332:1241-1245.
102. Volz HP, Baghai TC, Möller HJ 2006. Drug treatment of depression in the 2000s - an overview of achievements in the last ten years and future possibilities. World J Biol Psychiatry 7:198-222.
103. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F 2000. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 34: 171-181.